CTOs on the Move

Sunovion Pharmaceuticals

www.sunovion.com

 
Sunovion Pharmaceuticals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.sunovion.com
  • 84 Waterford Dr
    Marlborough, MA USA 01752
  • Phone: 508.481.6700

Executives

Name Title Contact Details
Daniel Joyce
 Senior Director, Information Security and Compliance Profile
Ben Howard
 Director - IT Security and Compliance Profile

Jobs

Vice President of Human Resources

Sunovion Pharmaceuticals Massachusetts
Sunovion is hiring a Vice President of Human Resources

Description:

The Vice President of Human Resources will serve as a trusted advisor to the organization on a range of business and organizational issues. The Vice President will lead the design and implementation of human resource strategies, initiatives, ...

Similar Companies

bellatrx

bellatrx is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Onyx Pharmaceuticals

At Onyx Pharmaceuticals, an Amgen subsidiary, our imperative is to build a leading cancer therapeutics company like no other, working toward a unified goal that drives us forward…to deliver breakthrough cancer treatments to patients with the urgency they deserve.   By working in collaboration with patient advocacy groups, healthcare providers and business partners, we push the boundaries of science and cancer therapeuticdevelopment.

Runatek

At Runatek, were ending the Opioid Crisis with innovative technology

SwitchGear Genomics (Main)

SwitchGear Genomics (Main) is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pieris

Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.